Materiality
72
earnings
Source
External coverage
Decided
2026-08-26
Eli Lilly raised 2026 guidance, but the market response appears muted amid valuation and growth-deceleration concerns. Lilly’s investor-relations release confirms the guidance increase ([primary source](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full)). Agilent appears as a comparable name, creating an issuer-metadata conflict.
View event details4 more curated